Galapagos NV (GLPG)
After hours:
| Previous Close | 43.67 |
| Open | 44.03 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 900 |
| Day's Range | 43.07 - 44.06 |
| 52 Week Range | 37.24 - 72.11 |
| Volume | |
| Avg. Volume | 167,945 |
| Market Cap | 2.867B |
| Beta (5Y Monthly) | 0.08 |
| PE Ratio (TTM) | 434.00 |
| EPS (TTM) | 0.10 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 54.56 |
- GlobeNewswire
Galapagos receives transparency notification from FMR LLC
Mechelen, Belgium; 10 January 2023, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 9 January 2023 from FMR LLC, who notified that it holds 3,903,804 of Galapagos’ voting rights, consisting of 3,801,504 ordinary shares and 102,300 equivalent financial instruments. FMR LLC controls investment funds Fidelity Management & Resea
- GlobeNewswire
Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference
Mechelen, Belgium; 3 January 2023, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 41th Annual J.P. Morgan Healthcare Conference on January 9-12, 2023. Paul Stoffels1, CEO, will present on Monday, January 9 at 4.30 p.m. PST/7.30 p.m. ET (Tuesday, January 10 at 01.30 a.m. CET). The presentation will be a live audio webcast and can be accessed via the following link. A replay of the webcast will be available on the Galapagos’ website at https://www.glpg.com/webcasts. Abou
- Zacks
3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
